Small Fiber Neuropathy.
Natalie Holmes StrandC WieJ PeckM MaitaN SinghJ DumbroffV Tieppo FrancioM MurphyK ChangD M DickersonJ MaloneyPublished in: Current pain and headache reports (2022)
While the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life.
Keyphrases
- neuropathic pain
- clinical practice
- spinal cord
- spinal cord injury
- randomized controlled trial
- end stage renal disease
- type diabetes
- human immunodeficiency virus
- hepatitis c virus
- chronic pain
- ejection fraction
- antiretroviral therapy
- clinical trial
- emergency department
- prognostic factors
- hiv infected
- hiv positive
- health information
- radiation therapy
- study protocol
- peritoneal dialysis
- social media
- wound healing
- rectal cancer
- replacement therapy
- postoperative pain